Oppenheimer Begins Coverage on Ocugen (NASDAQ:OCGN)

Equities researchers at Oppenheimer initiated coverage on shares of Ocugen (NASDAQ:OCGN) in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $10.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 327.35% from the company’s previous close.

A number of other equities research analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a report on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Ocugen in a research note on Thursday, March 5th. Finally, Wall Street Zen lowered shares of Ocugen from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Ocugen Stock Performance

NASDAQ OCGN opened at $2.34 on Wednesday. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06. The stock’s fifty day moving average is $1.63 and its two-hundred day moving average is $1.45. The firm has a market capitalization of $767.29 million, a P/E ratio of -10.17 and a beta of 2.75. Ocugen has a fifty-two week low of $0.51 and a fifty-two week high of $2.44.

Ocugen (NASDAQ:OCGN) last issued its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.The business had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.86 million. On average, research analysts anticipate that Ocugen will post -0.2 earnings per share for the current year.

Institutional Trading of Ocugen

Hedge funds and other institutional investors have recently modified their holdings of the business. SmartHarvest Portfolios LLC purchased a new stake in Ocugen in the 4th quarter valued at about $31,000. Schonfeld Strategic Advisors LLC purchased a new position in Ocugen during the fourth quarter worth about $38,000. Verdence Capital Advisors LLC purchased a new position in Ocugen during the third quarter worth about $47,000. Cora Capital Advisors LLC increased its position in shares of Ocugen by 27.5% during the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after acquiring an additional 6,500 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Ocugen by 28,222.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock valued at $41,000 after acquiring an additional 30,198 shares during the period. 10.27% of the stock is owned by institutional investors and hedge funds.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Oppenheimer initiated coverage with an Outperform rating and a $10 price target, calling Ocugen an emerging gene‑therapy leader in blinding ocular disorders — a high‑profile analyst endorsement and large implied upside that typically attracts investor interest. Oppenheimer Initiates Coverage
• Positive Sentiment: Unusual options activity: traders bought ~5,566 call contracts (≈62% above average), signaling speculative bullish positioning that can amplify short‑term upside in the stock. (Market activity report)
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates (Q1–Q4 2026 and FY2026) — modest upward revisions to quarterly/near‑term forecasts suggest analysts see improving fundamentals or lower near‑term dilution risk. HC Wainwright Estimates
• Neutral Sentiment: HC Wainwright published a FY2030 earnings estimate (long‑range forecast) — long‑horizon projections are useful for modeling but carry high uncertainty for a clinical‑stage biotech, so immediate market impact is limited. FY2030 Estimate
• Negative Sentiment: HC Wainwright cut several longer‑term forecasts (FY2027–FY2029, FY2028 revisions), including a materially lower FY2029 EPS view — this reduces long‑term upside assumptions and signals greater uncertainty about commercial timing or pipeline readouts. HC Wainwright Long‑Term Revisions

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.